Luke

“Could you provide a little more color on your confidence in the timing of the planned PSC submission? What's the next regulatory touchstone you should be looking for here?”

“Just one quick one on business development strategy. Can you provide any color on particular areas of interest within rare disease or with regard to development stage you'd be looking for, or would you say you're fairly agnostic?”

“So you noted that Levitus or the business has stabilized. Does a return to growth assume only access in the ambulatory setting, or does that growth assume that you're able to resume treatment in non-animal patients?”

“We have a broader question on the DM1 indication, just hoping for some insight on understanding of the importance of numerical splice correction data, just thinking about both clinical impact and the perspective of regulators.”